e-learning
resources
Barcelona 2010
Wednesday, 22.09.2010
Staging of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC)
T. Win, M. Shastry, R. Endozo, S. Janes, I. Kayni, P. Ell, K. Miles, A. Groves (Stevenage, , Brighton, United Kingdom)
Source:
Annual Congress 2010 - Staging of lung cancer
Session:
Staging of lung cancer
Session type:
E-Communication Session
Number:
5449
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Win, M. Shastry, R. Endozo, S. Janes, I. Kayni, P. Ell, K. Miles, A. Groves (Stevenage, , Brighton, United Kingdom). Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC). Eur Respir J 2010; 36: Suppl. 54, 5449
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Imaging of eosinophilic lung disease
Related content which might interest you:
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Effects of prognostic factors on survival of the patients of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006
HER2/
Neu
overexpression as independent negative prognostic factor for non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept